ZimVie sales down more than 11% in Q2 as it streamlines after spinoff
10 Aug 2022
CEO Vafa Jamali told MassDevice and Medical Design & Outsourcing on March 1 — ZimVie’s first day of public trading — that initial tasks in the company’s spine tech business included pulling out of countries that had proved unprofitable. There were also some spine product discontinuations.
Coupled with a strong U.S. dollar causing headwinds for the dental tech side of the business, ZimVie’s losses roughly doubled year-over-year to $8.7 million, or 33¢ per share, for the quarter ended June 30, 2022. Sales were down 11.5% year-over-year to $233.4 million.
ZimVie reported adjusted EPS of 67¢. Yahoo Finance presently lists one analyst revenue prediction for the quarter who expected $238.3 million in sales.
“We continue to make progress towards our most vital commercial initiatives in both our dental and spine segments” Jamali said in a news release out after market close. “Within dental, we recently launched two highly innovative products: the T3 PRO tapered implant and the Encode emergence healing abutment. Within spine, we received a major positive insurance policy decision from Anthem Blue Cross Blue Shield for The Tether, a device for treatment of pediatric scoliosis, expanding insurance coverage for up to 30 million lives.”
Jamali added: “We are also tracking to our plan to improve the short- and long-term operational efficiency of our newly independent company.”
Facing greater than anticipated foreign exchange headwinds, ZimVie is reducing its full-year revenue forecast to $915 to $930 million versus prior guidance of $1 billion.
The company is also cutting its adjusted EPS guidance to $2.10 to $2.30 from a previous $1.80 to $2.00 amid lower sales.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.